Market Closed - Nasdaq 04:00:00 2024-05-02 pm EDT 5-day change 1st Jan Change
75.91 USD -0.49% Intraday chart for Hologic, Inc. +0.26% +6.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hologic Fiscal Q2 Earnings, Revenue Decline; Q3 Outlook Issued, Fiscal 2024 Estimates Revised -- Shares Up After Hours MT
Transcript : Hologic, Inc., Q2 2024 Earnings Call, May 02, 2024
Earnings Flash (HOLX) HOLOGIC Posts Q2 EPS $1.03, vs. Street Est of $0.98 MT
Earnings Flash (HOLX) HOLOGIC Reports Q2 Revenue $1.02B, vs. Street Est of $1B MT
(HOLX) HOLOGIC Expects Fiscal Year 2024 EPS Range $4.02 - $4.12 MT
(HOLX) HOLOGIC Sees Q3 EPS Range $0.98 - $1.05 MT
Hologic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 30, 2024 CI
Molten Ventures portfolio firm gets bought by Hologic AN
Molten Ventures portfolio firm to buy Endomagnetics for USD310 million AN
Hologic to Acquire Breast Cancer Surgery Technology Firm Endomagnetics For $310 Million MT
Hologic, Inc. signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million. CI
Bayer and Hologic Collaborates to Deliver Contrast-Enhanced Mammography CI
Transcript : Hologic, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-09-2024 11:45 AM
RBC Raises Price Target on Hologic to $81 From $76, Keeps Sector Perform Rating MT
North American Morning Briefing : Focus Turns to -2- DJ
Citigroup Upgrades Hologic to Buy From Neutral, Raises Price Target to $95 From $80 MT
Watching for Indications of a Changed Fed Outlook; Plus, How One Company Avoided Mass Layoffs DJ
Hologic Insider Sold Shares Worth $1,241,296, According to a Recent SEC Filing MT
Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test CI
Transcript : Hologic, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-04-2024 08:40 AM
FDA warns of potential risk from Hologic's devices implanted in soft tissue RE
FDA warns of potential risk of complications with use of Hologic's devices RE
UBS Adjusts Hologic's Price Target to $79 From $78, Maintains Neutral Rating MT
Needham Adjusts Price Target on Hologic to $90 From $83, Maintains Buy Rating MT
Tranche Update on Hologic, Inc.'s Equity Buyback Plan announced on September 23, 2022. CI
Chart Hologic, Inc.
More charts
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - breast health (35.5%): digital mammography and breast biopsy solutions and systems; - gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment. Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%). Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
75.91 USD
Average target price
84.43 USD
Spread / Average Target
+11.22%
Consensus
  1. Stock Market
  2. Equities
  3. HOLX Stock
  4. News Hologic, Inc.
  5. RBC Trims Price Target on Hologic to $85 From $87, Maintains Sector Perform Rating